The Role of the GP in the Management of Ambulatory Heart Failure

Recruiting

• Conditions: Heart Failure

• Registration Number: NCT05056649
• Lead Sponsor: Jean-Marc BOIVIN

Brief Summary

To describe the causes mentioned by general practitioners, explaining the under-treatment of the three main treatments for heart failure with impaired ejection fraction (ARS blockers of the type ACEinhibitor/ARA2/ARNi, ß- and/or anti-aldosterone).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-05-11
• Study First Submitted QC: 2021-09-23
• Study First Posted: 2021-09-24
• Study Start: 2022-10-01
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-20
• Last Update Posted: 2023-06-22
• Primary Completion: 2023-09-01
• Study Completion: 2023-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patients with a previous diagnosis of heart failure with impaired ejection fraction (LVEF < 40%)
• Under 85 years of age
• Admitted to an Emergency department for cardiac decompensation
• Hospitalized following this decompensation
• Not deceased within one month of hospitalisation
• Whose sum of the doses of ACEI or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient* (definition in annex)
• Who did not object within one month of being informed

Exclusion Criteria

• Patient objecting to the use of their data

• Patient who is a minor
• Patient who does not have a general practitioner

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quantitative analysis of verbatims after grouping	Through study completion, an average of 1 year

Trial Locations

Locations (1)

CHRU of Nancy; 🇫🇷 Vandœuvre-lès-Nancy, France